Impact of age and induction therapy on outcome of 180 adult patients with acute myeloid leukemia; retrospective analysis and literature review

Khadega A. Abuelgasim⁎, Bandar Albuhayri, Rayan Munshi, Areej Al Mugairi, Bader Alahmari, Giamal Gmati, Hind Salama, Mohsen Alzahrani, Ayman Alhejazi, Ahmed Alaskar, Moussab Damlaj

⁎Corresponding author
E-mail address: ahmedkh1@ngha.med.sa (K.A. Abuelgasim).

https://doi.org/10.1016/j.lrr.2020.100206

1. Introduction

The incidence of acute myeloid leukemia (AML) is increasing with some improvement in mortality rates over decades due to the development on new anti-leukemia drugs and the improvement in management of chemotherapy and allogeneic stem cell transplant (allo-HSCT) complications [1]. The prognosis of AML, however, remains poor with an overall 5-year survival (OS) of 28.3%; while the OS is 40–50% in patients younger than 50 with de novo AML, the OS for elderly is only 5–10% [1–3].

AML prognosis depends on pretreatment factors such as age and cytogenetics upon diagnosis and post-treatment prognostic factors such as response to induction and more recently minimal residual disease [4–6]. Approximately 65% of newly diagnosed AML will have an abnormal karyotype at the time of diagnosis, with older patients having higher incidence of high-risk cytogenetics compared to the young [7,8]. Age impact on the outcome of AML patients is not only related to cytogenetics, but also performance status at diagnosis, with treatment related deaths up to 19% in patients above age 55 [9]. Older patients with AML are less likely to achieve complete remission (CR) after induction chemotherapy and they are more likely to experience disease relapse even if CR is attained [10]. Many elderly AML patients may not qualify for remission induction and an even fewer might qualify for consolidative allogeneic hematopoietic stem cell transplantation (SCT) [6].

In the present study we aimed to study the outcome of AML patients diagnosed at King Abdulaziz Medical City, Riyadh with emphasis on outcome in different age groups particularly the elderly.

2. Methodology

2.1. Patient selection

After due institutional review board approval, all patients ≥ 14 years of age with confirmed AML in the period of 2000–2018 were identified; and all records were retrospectively extracted.
2.3. Induction chemotherapy

Patients received standard induction (SI) consistent of seven days of cytarabine at a dose of 200 mg/m² plus three days of idarubicin at a dose of 12 mg/m² twice per day (7 + 3) if they were younger than 65 and they are deemed fit to be able to tolerate high dose chemotherapy. Those with co-morbidities received reduced induction (RI) in the form of either five days of cytarabine at a dose of 100 mg/m² plus two days of idarubicin at a dose of 12 mg/m² twice per day (5 + 2) or intermediate dose cytarabine at a dose of 1500 mg/m² twice a day for three days for a total of six doses on days one, three and five. Patients with poor performance status, those with multiple comorbidities and those older than 70 years of age were treated with 5-azacitidine (AZA) or palliative therapy (PC) which could consist of supportive care with or without low doses of chemotherapy.

2.4. Response assessment and definitions

At count recovery or on day 28 post-chemotherapy, whichever comes first, a bone marrow aspiration and biopsy were performed to assess the disease response. Response criteria were defined as per the ELN 2017 criteria [11]. CR was defined as the presence of 5% or less bone marrow blasts, absence of circulating blasts and blasts with auer rods, absence of extramedullary disease, absolute neutrophil count (ANC) ≥1.0 × 10⁹/L (1000/µL); platelet count ≥100 × 10⁹/L (100 000/µL). CR with incomplete hematologic recovery (CRi) was assessed as bone marrow blasts <5%; absence of circulating blasts and blasts with auer rods; absence of extramedullary disease except for residual neutropenia (<1.0 × 10⁹/L [1000/µL]) or thrombocytopenia (<100 × 10⁹/L [100 000/µL]). Primary refractory disease was defined as no CR or CRi after two courses of intensive induction treatment; excluding patients with death in aplasia or death due to indeterminate cause. Death in aplasia was defined as death occurring ≥7 d following completion of initial treatment while cytopenic. Disease relapse was defined as hematologic relapse (after CR, CRi); bone marrow blasts ≥5%, reappearance of blasts in the blood or development of extramedullary disease.

2.5. Consolidative therapy and allogeneic SCT

The consolidative therapy was decided based on whether the patient is a candidate for consolidative SCT, the disease characteristics (risk stratification), the response to induction therapy and the availability of a matched donor. SCT was recommended for all high and intermediate risk groups based on the ELN risk stratification if patient is eligible and donor available [11]. Matched related donor (MRD) was preferred over matched unrelated donor (MUD) over haploidentical donor.

2.6. Statistical analysis

Overall survival (OS) was calculated from the date of the start of induction chemotherapy until the date of death of any cause or last documented follow-up. Disease free survival (DFS) was calculated from the delivery of induction chemotherapy until death of any cause or evidence of disease relapse. Baseline patient, disease and treatment related variables were reported using descriptive statistics (counts, medians and percentiles). Categorical and continuous variables were compared using Pearson’s chi-squared and Wilcoxon / Kruskal-Wallis, respectively. Probability of OS and DFS was computed using the Kaplan-Meier method. Group comparisons were made using the log-rank test. Statistical analyses were performed using JMP Pro-Version 11 (SAS Institute, Cary, NC, USA) software and EZR on R commander.

3. Results

3.1. Patient characteristics

A total of 180 patients were identified through a query of our Oncology database. The median age at diagnosis was 53 (14-88) years and 103 (57%) were males. The age distribution was as follows; 58 (32%) were between 14–40 years, 57 (32%) between 41–60 years and the remaining 65 (36%) were over 60 years of age. Co-morbidities were present in 73 (41%) of patients including 8 (5%) of patients with 3 or more co-morbidities. The median Eastern Cooperative Oncology Group (ECOG) status was 1 (0–4). The World Health Organization (WHO) leukemia subtype was as follows; 91 (51%) with recurrent genetic abnormality, 31 (17%) AML with myelodysplasia related changes, 56 (31%) AML not otherwise specified (NOS) and 2 (1%) were therapy related disease. Risk stratification was as follows; 39 (22%) had favourable disease, 79 (43%) had intermediate disease, 50 (28%) had poor risk disease and there were 12 (7%) with unknown status due to various factors such as failed cytogenetics, dry aspirate and referral from another center.

With regards to induction therapy, 109 (60%) patients received SI, 32 (18%) received RI, 21 (12%) received AZA while 18 (10%) received PC. Median follow-up was 16.3 months (0.16–168.3) for all patients and 36.1 months (2.3–168.3) for alive patients. Outcome post induction was as follows; 112 (62%) achieved CR/CRI post first induction, 32 (18%) had primary refractory disease while 13 (7%) died in aplasia; and 62 (34%) underwent allogeneic SCT. The baseline characteristics and induction outcome of the whole cohort are detailed Table 1. The 2-year DFS for the entire cohort was 28.6% +/- 3.4 whereas the 2-year OS for the entire cohort was 45.3% +/- 3.8%.

Table 1

| Characteristic | N = 180 |
|---------------|---------|
| Age, median (range) | 53 (14-88) |
| Age, n (%) | |
| 14–40 | 58 (32) |
| 41–60 | 57 (32) |
| ≥ 61 | 65 (36) |
| Male, n (%) | 103 (57) |
| Co-morbidities | |
| 0 | 106 (59) |
| 1–2 | 65 (36) |
| ≥ 3 | 8 (5) |
| ECOG, median (range) | 1 (0–4) |
| WHO Subtype, n (%) | |
| Recurrent Genetic Abnormality | 91 (51) |
| AML with MDS | 31 (17) |
| AML NOS | 56 (31) |
| Therapy Related | 2 (1) |
| Risk Stratification, n (%) | |
| Favorable | 39 (22) |
| Intermediate | 79 (43) |
| Poor | 50 (28) |
| Unknown | 12 (7) |
| Induction Type | |
| Standard Induction | 109 (60) |
| Reduced Induction | 32 (18) |
| 5-AZA | 21 (12) |
| Palliative | 18 (10) |
| Induction Outcome, n (%) | |
| CR/CRI | 112 (62) |
| Primary Refractory | 32 (18) |
| Death in Aplasia | 13 (7) |
| Unknown | 23 (13) |
| Allogeneic SCT, n (%) | 62 (34) |
3.2. Outcome in different age groups

Patient, disease and therapy baseline was stratified by age and results as follows; Fifty-eight (32%) patients were 40 years old or younger, 57 (32%) patients were 41–60 years and 65 (36%) were older than age 60 at the time of diagnosis. Overall, baseline co-morbidities were higher in the older age groups (p < 0.0001) and a worse ECOG status (p < 0.0001). Incidence of higher risk disease was also more common with age (p = 0.04).

Treatment offered also differed based on underlying age. Among the young and middle age groups 100 (87%) received SI, 9 (8%) received RI while 6 (5%) received AZA or PC. Among the same group, 86 (75%) achieved CR/CRI at the end of induction and 59 (51%) underwent autologous SCT. While 6 (5%) received AZA or PC. Among the same group, 86 (75%) were significantly higher in the young and middle age groups than older at 91%, 82% and 14%, respectively (p < 0.0001). Furthermore, a significantly inferior induction outcome was noted in the latter group with lower incidence of CR/CRI and higher incidence of death in aplasia (p = 0.0002). Use of allogeneic SCT was also significantly varied among the three groups at 64%, 39% and 5% for the younger, middle age and older groups; respectively, (p < 0.0001). These results are shown in Table 2.

The 2-year DFS stratified by age groups was 47.7% + /- 6.6% for patients younger than 40 years, 23.6% + /- 5.8% for 41–60 years and 11.7% + /- 4.2% > 61 years (p<0.0001). The 2-year DFS compared between different age groups was ≤ 40 vs. ≥ 61 HR 0.32 (0.2-0.49; < 0.0001); 41–60 vs. ≥ 61 HR 0.66 (0.44-0.97; 0.037); ≤ 40 vs. 41–60 HR 0.48 (0.3-0.75; 0.0014). The 2-year OS stratified by age groups was 78.6% + /- 5.5% for patients younger than 40 years, 43.5% + /- 6.9% for 41–60 years and 15.8% + /- 4.8% > 61 years (p<0.0001). The 2-year OS compared between different age groups was ≤ 40 vs. ≥ 61 HR 0.15 (0.087-0.27; < 0.0001); 40–60 vs. ≥ 61 HR 0.49 (0.32-0.76; 0.0001); ≤ 40 vs. 40–60 HR 0.31 (0.17-0.55; < 0.0001). The 2-year DFS stratified by age groups is shown in Fig. 1.

3.3. Outcome in elderly AML

Given the heterogeneity in therapy delivered most seen in the elderly group, we stratified them based on therapy. We observed a significant difference in the following variables; median age was youngest in the SI and oldest in the AZA / PC groups (p < 0.0001), ECOG highest in the AZA / PC groups (p = 0.04) and induction outcome was best in the SI / RI groups (p < 0.0001). The 2-year DFS stratified by type of induction was as follows: standard vs. reduced HR 0.43 (0.28-0.67; 0.0002); palliative vs. 5-AZA HR 0.48 (0.24-0.96; 0.04); standard vs. palliative HR 0.56 (0.32-1; 0.051). The 2-year OS stratified by type of induction was as follows: standard vs. reduced HR 0.37 (0.22-0.6; < 0.0001); palliative vs. 5-AZA 0.42 (0.2-0.86; 0.018); standard vs. palliative 0.39 (0.21-0.71; 0.0024). Allogeneic SCT was offered to 3 patients only, all of whom received SI. These results are shown in Table 3.

The 2-year DFS in patients > 60 years old stratified by therapy were as follows; SI 22.2% + /- 7.9%, RI 17.4% + /- 7.9%, AZA 0% and PC 7.7% + /- 7.4 (p = 0.032). The 2-year OS were as follows; SI 22.2% + /- 17.7%, RI 22.9% + /- 8.9%, AZA 0% and PC 9.6% + /- 8.9%. These results are shown in Fig. 2.

4. Discussion

AML is a common malignancy among adult patients with an estimated total of 21,450 newly diagnosed cases and 10,920 deaths in the United States alone in 2019 [1]. For over 3 decades, the backbone of induction therapy consisted of anthracycline and cytarabine combination which was originally reported in 1973[12,13]. However, recent advances in descriptive mutational classification have led to the development of multiple new AML targeted therapies. During 2017 and 2018 alone the US Food and Drug Administration (FDA) approved one combination drug (CPX-351) and seven new drugs to treat AML (glasdegib, midostaurin, venetoclax, enasidinib, gilteritinib, gemtuzumab ozogamicin and ivosidenib) [14]. However, experience with those agents remains limited as we need further studies to optimize their use with other drugs including chemotherapy. The 5-year overall survival has improved for AML patients due to a number of factors including improvements in supportive care. This has not equated among different age groups [1,15-17]. For instance, the 5- and 10-year survival for adolescents and young adult patients (15–34 years) is 52.3% and 47.9%. Yet, they are only 36.6% and 33.6% for middle age (35–54 years), 19.9% and 17.9% for (55–64 years) age group and only 9.2% and 4.5% for elderly (65–74 years) [17].

In the present study, the median age at diagnosis was 53 (14-88) years much younger compared to the United Kingdom which was reported by Roman et al. where median age at diagnosis of all 5231 myeloid subtypes combined being 72.4 years (IQR 61.5–80.2 years) and older than in India as reported by Phillips et al.: the median age among 380 newly diagnosed AML patients was 40 years (range: 1–79; 12% were ≤ 15 years, 16.3% were ≥ 60 years old) and there were 244 (64.2%) males [18,19]. A recent study reporting the outcome of 135 newly diagnosed AML patients in the Western Region of Saudi Arabia median age of 42 years (range 14–67) relatively younger than our cohort. The age distribution was as follows; 58 (32%) were between 14–40 years, 57 (32%) between 41–60 years and the remaining 65 (36%) were over 60 years of age. Our cohort has more elderly patients compared to what was reported by Alabdulwahab et al. where 65 (48.1%) patients were < 42 years, and only 11 (8.2%) > 60 years [20].

In the present analysis, 109 (60%) patients achieved CR/CRI at end of induction. The percentage of patients who achieved CR/CRI was similar in patients younger than age 40 and those 41–60: 45(78%) vs. 41(72%); compared to only 25 (38%) in patients older than age 60. Nonetheless, the long term outcome of the middle age group patients is
more comparable to that of elderly group despite the fact that two thirds of them presented with favorable or intermediate risk score, 82% received SI, and 39% underwent allo-HSCT. The 2-year DFS for those 41–60 was much lower compared with patients younger than 40 years, 23.6% +/- 6.6%. The DFS compared among the three age groups was as follows: ≤40 years vs. ≥61 years HR 0.32 (0.2–0.49; < 0.0001); 40–60 years vs. ≥61 years HR 0.66 (0.44–0.97; 0.037); ≤40 years vs. 40–60 years HR 0.48 (0.3–0.75; 0.0014). The 2-year OS for those 41–60 was 43.5% +/- 6.9% for patients younger than 40 years, 47.7% +/- 6.6% for patients younger than 40 years, 23.6% +/- 5.8% for 41-60 years and 11.7% +/- 4.2% > 61 years (p< 0.0001). The 2-year OS stratified by age groups was 78.6% +/- 5.5% for patients younger than 40 years, 43.5% +/- 6.9% for 41-60 years and 15.8% +/- 4.8% > 61 years (p< 0.0001).

Table 3
Baseline characteristics of patients ≥61 years stratified by type of therapy.

| Characteristic / Treatment group | Standard induction (n = 9) | Reduced induction (n = 23) | 5-AZA (n = 20) | Palliative (n = 13) | P value |
|----------------------------------|---------------------------|---------------------------|---------------|------------------|---------|
| Male, n (%)                      | 9 (100)                   | 15 (65)                   | 13 (65)       | 6 (46)           | 0.02    |
| Age, median (range)              | 62 (61–69)                | 68 (62–76)                | 74 (61–88)    | 70 (63–88)       | < 0.0001|
| Co-morbidities                   |                           |                           |               |                  | 0.3     |
| 0                                | 5 (56)                    | 6 (26)                    | 4 (21)        | 2 (15)           |         |
| 1–2                              | 4 (44)                    | 13 (57)                   | 13 (68)       | 9 (69)           |         |
| ≥ 3                              | 0                         | 4 (17)                    | 2 (11)        | 2 (15)           |         |
| ECOG, median (range)             | 1 (0–2)                   | 1 (0–4)                   | 3 (0–4)       | 3 (1–4)          | 0.0006  |
| WHO Subtype, n (%)               |                           |                           |               |                  | 0.04    |
| Recurrent Genetic Abnormality    | 6 (67)                    | 12 (52)                   | 8 (40)        | 5 (38.5)         |         |
| AML with MDS                     | 1 (11)                    | 1 (4)                     | 8 (40)        | 5 (38.5)         |         |
| AML NOS                           | 2 (22)                    | 10 (44)                   | 4 (20)        | 3 (23)           |         |
| Risk Stratification, n (%)       |                           |                           |               |                  | 0.08    |
| Favorable                        | 0                         | 4 (17)                    | 1 (5)         | 3 (23)           |         |
| Intermediate                     | 3 (33.3)                  | 11 (48)                   | 10 (50)       | 3 (23)           |         |
| Poor                             | 3 (33.3)                  | 6 (26)                    | 9 (45)        | 5 (39)           |         |
| Unknown                          | 3 (33.3)                  | 2 (9)                     | 0             | 2 (15)           | < 0.0001|
| Induction Outcome, n (%)         |                           |                           |               |                  |         |
| CR/CRi                           | 6 (67)                    | 16 (69)                   | 1 (5)         | 2 (15)           |         |
| Resistant Disease                | 3 (33)                    | 2 (9)                     | 8 (40)        | 2 (15)           |         |
| Death in Aplasia                 | 0                         | 3 (13)                    | 3 (15)        | 2 (15)           |         |
| Unknown                          | 0                         | 2 (9)                     | 8 (40)        | 8 (54)           |         |
| Allogeneic SCT, n (%)            | 3 (33)                    | 0                         | 0             | 0                | 0.005   |

Fig. 1. Two-year disease-free survival and overall survival stratified by age groups. The 2-year DFS was 47.7% +/- 6.6% for patients younger than 40 years, 23.6% +/- 5.8% for 41-60 years and 11.7% +/- 4.2% > 61 years (p< 0.0001). The 2-year OS stratified by age groups was 78.6% +/- 5.5% for patients younger than 40 years, 43.5% +/- 6.9% for 41-60 years and 15.8% +/- 4.8% > 61 years (p< 0.0001).

Fig. 2. Two-year disease-free survival and overall survival in patients older than 60 years old stratified by therapy. The 2-year DFS was 22.2% +/- 7.9% for standard induction (SI), 17.4% +/- 7.9% for reduced induction (RI), 0% for azacytidine and 7.7% +/- 7.4 for palliative care (PC) (p = 0.032). The 2-year OS were as follows: 22.2% +/- 17.7% for SI, 22.9% +/- 8.9% for RI, 0% for AZA and 9.6% +/- 8.9% for PC.
agents or in combination with hypomethylating agents for remission
leukemia. Inosidenib and enasidenib are being studied as single
molecular inhibitors. In the present cohort, only few elderly patients received venetoclax, and none received
venetoclax. The introduction of sequencing technologies had shown major dif-
ferences in the cytogenetic and mutational profile of AML in the elderly
[29,30]. The methylation patterns in such patients is similar to those
seen in MDS patients [31]. These unique features may help scientist
design more targeted therapies for such patient population. The
BCL-2 inhibitor venetoclax combined with azacitidine or decitabine have
resulted in an overall response rate of 59–65% with a median OS of 17.5
months with no additional adverse events compared to azacitidine or
decitabine alone [32]. The addition of gemtuzumab ozogamicin (GO)
induction chemotherapy had been shown to reduce the relapse rate and
to improve the survival of favorable and intermediate risk AML patients both young and old [33]. GO combined to azacitidine was shown to be
of benefit in older AML patients with poor risk [34]. In the present
cohort, only few elderly patients received venetoclax and none received
GO.

The isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) small mol-
ecular inhibitors ivosidenib and enasidenib are being studied as single
agents or in combination with hypomethylating agents for remission
induction in newly diagnosed AML with patients harboring IDH1 or
IDH2 mutations. If combination therapy is proven to be of benefit, these
drugs can will be a great plus to elderly AML induction therapy
armamentarium. In front line setting two studies have shown an
improved outcome with the addition of FLT3 inhibitors (sunitinib and
quizariznib) to chemotherapy in elderly patients with FLT3-ITD-mu-
tated AML [35,36].

Although more than half of the patients achieved CR at the end of
induction, only patients younger than 40 had durable DFS and OS.
Middle age group AML patients do much worse compared to the young
and special intervention need to be implemented to improve the out-
come of this age group. More options are available than ever before for

CRediT authorship contribution statement

Khadeja A. Abuelgasim: Conceptualization, Methodology, Data
curation, Writing - original draft. Bandar Albuhayri: Conceptualization,
Data curation, Writing - original draft. Rayan Munshi: Conceptualization,
Data curation, Writing - original draft. Areej Al Mugairi: Conceptualization,
Data curation, Writing - review & editing. Bader Alahmari: Conceptualization,
Writing - review & editing. Giamal Gmati: Writing - review & editing. Hind Salama:
Writing - review & editing. Mohsen Alzahrani: Writing - review & editing. Ayman Alhejazi:
Supervision, Writing - review & editing. Ahmed Alaskar: Supervision, Writing - review & editing. Moussab
Damlaj: Conceptualization, Supervision, Formal analysis, Writing -
review & editing.

Declaration of Competing Interests

The authors declare no conflict of interest.

Acknowledgement

No writing assistance needed.

References

[1] Howlader N.N.A., Krupche M., Miller D., Brest A., Yu M. et al. SEER cancer statistics
review. National Cancer Institute Bethesda, MD 1975–2016.

[2] A. Burnett, M. Wetzler, B Lowenberg, Therapeutic advances in acute myeloid leu-
kemia, J. Clin. Oncol. 29 (5) (2011) 487–494.

[3] H. Dohner, D.J. Weisdorf, C.D Bloomfield, Acute myeloid leukemia, N. Engl. J. Med.
373 (12) (2015) 1136–1152.

[4] Grimwade D. Impact of cytogenetics on clinical outcome in AML. Acute myelo-
genous leukemia 2007;pp 177–92.

[5] S.D. Freeman, J.V. Jovanovic, D Grimwade, Development of minimal residual dis-
ease-directed therapy in acute myeloid leukemia, Semin. Oncol. 35 (4) (2008)
388–400.

[6] J.M. Rowe, Optimal induction and post-remission therapy for AML in first remis-
sion, Hematol. Am. Soc. Hematol. Educ. Progr. (2009) 396–405.

[7] K. Mrozek, G. Marchetti, P. Paschka, S.P. Whitman, C.D Bloomfield, Clinical re-
levance of mutations and gene-expression changes in adult acute myeloid leukemia
with normal cytogenetics: are we ready for a prognostically prioritized molecular
classification? Blood 109 (2) (2007) 431–448.

[8] D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C.J. Harrison, et al.,
The predictive value of hierarchical cytogenetic classification in older adults with
acute myeloid leukemia (AML): analysis of 1065 patients entered into the United
Kingdom medical research council AML11 trial, Blood 98 (5) (2001) 1512–1520.

[9] F.R. Appelbaum, H. Gundacker, D.R. Head, M.L. Slovak, C.L. Willman, J.E. Godwin,
et al., Age and acute myeloid leukemia, Blood 107 (9) (2006) 3481–3485.

[10] E. Estey, Acute myeloid leukemia and myelodysplastic syndromes in older patients,
J. Clin. Oncol. 25 (14) (2007) 1908–1915.

[11] H. Dohner, E. Estey, D. Grimwade, S. Amadori, F.R. Appelbaum, T. Buchner, et al.,
Diagnosis and management of AML in adults: 2017 EHN recommendations from an
international expert panel, Blood 129 (4) (2017) 424–447.

[12] A.K. Burnett, D. Milligan, A.G. Premice, A.H. Goldstone, M.F. McMullin, R.K. Hills,
et al., A comparison of low-dose cytarabine and hydroxyurea with or without all-
trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syn-
drome in patients not considered fit for intensive treatment, Cancer 109 (6) (2007)
1114–1124.
[13] M.A. Lichtman, A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukaemia: 2013 the 40th anniversary of 7 + 3, Blood Cells Mol. Dis. 50 (2) (2013) 119–120.

[14] E. Estey, J.E. Karp, A. Emadi, M. Othus, R.P. Gale, Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia 34 (3) (2020) 671–681.

[15] A.R. Derolf, S.Y. Kristinsson, T.M. Andersson, O. Landgren, P.W. Dickman, E. Estey, J.E. Karp, A. Emadi, M. Othus, R.P. Gale, Recent drug approvals for newly diagnosed acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005, Blood 113 (16) (2009) 3666–3672.

[16] M. Sani, P. Miniccozi, M. Mounier, L.A. Anderson, H. Brenner, B. Hollerczak, et al., Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study, Lancet Oncol. 15 (9) (2014) 931–942.

[17] D. Pulte, A. Gondos, H Brenner, Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century, Haematologica 93 (4) (2008) 594–600.

[18] C. Philip, B. George, A. Ganapule, A. Korula, P. Jain, A.A. Alex, et al., Acute myeloid leukemia: challenges and real world data from India, Br. J. Haematol. 170 (1) (2015) 110–117.

[19] E. Roman, A. Smith, S. Appleton, S. Crouch, R. Kelly, S. Kinsey, et al., Myeloid malignancies in the real-world: occurrence, progression and survival in the UK’s population-based haematological malignancy research network 2004-15, Cancer Epidemiol. 42 (2016) 186–198.

[20] A.S. Alabdulwahab, H.G. Elsayed, M.A. Sherisher, A. Zeeneldin, W.M Elbjeirami, Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the acute leukemia working party of the EBMT, Haematologica 100 (7) (2015) 859–869.

[21] J.P. Patel, M. Goneen, M.E. Figueroa, H. Fernandez, Z. Sun, J. Racevskis, et al., Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N. Engl. J. Med. 366 (12) (2012) 1079–1089.

[22] B.C. Medeiros, S. Satram-Hoang, D. Hurst, K.Q. Hoang, F. Momin, C Reyes, Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States, Ann. Hematol. 94 (7) (2015) 1127–1138.

[23] G. Julisson, P. Antunovic, A. Derolf, S. Lehmann, L. Mollgard, D. Stockelberg, et al., Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry, Blood 113 (18) (2009) 4179–4187.

[24] B. Oran, D.J. Weisdorf, Survival for older patients with acute myeloid leukemia: a population-based study, Haematologica 97 (12) (2012) 1916–1924.

[25] H. Dombret, J.F. Seymour, A. Butrym, A. Wierzbowska, D. Selleslag, J.H. Jang, et al., International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood 126 (3) (2015) 291–299.

[26] H.D. Klepin, A.V. Rao, T.S Pardee, Acute myeloid leukemia and myelodysplastic syndromes in older adults, J. Clin. Oncol. 32 (24) (2014) 2541–2552.

[27] H.D. Klepin, A.M. Geiger, J.A. Tooze, S.B. Kitchevsky, J.D. Williamson, T.S. Pardee, et al., Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia, Blood 121 (21) (2013) 4287–4294.

[28] S. Sengsayadeth, B.N. Savani, D. Blaise, F. Malard, A. Nagler, M. Mohty, Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the acute leukemia working party of the EBMT, Haematologica 100 (7) (2015) 859–869.

[29] J.F. Patel, M. Goneen, M.E. Figueroa, H. Fernandez, Z. Sun, J. Racevskis, et al., Prognostic relevance of integrated genetic profiling in acute myeloid leukemia, N. Engl. J. Med. 366 (12) (2012) 1079–1089.

[30] A.V. Rao, P.J. Valk, K.H. Metzeler, C.R. Acharaya, S.A. Tuchman, M.M. Stevenson, et al., Age-specific differences in oncogenic pathway dysregulation and anthrapyline sensitivity in patients with acute myeloid leukemia, J. Clin. Oncol. 27 (33) (2009) 5580–5586.

[31] M.E. Figueroa, L. Skrabanek, V. Li, A. Jemijit, T.E. Fandy, E. Pajetra, et al., MDS and secondary AML display unique patterns and abundance of aberrant DNA methylations, Blood 114 (16) (2009) 3448–3458.

[32] C.D. DiNardo, K. Pratz, V. Pullarkat, B.A. Jonas, M. Arellano, P.S. Becker, et al., Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia, Blood 133 (1) (2019) 7–17.

[33] R.K. Hills, S. Castaigne, F.R. Appelbaum, J. Delaunay, S. Petersdorf, M. Othus, et al., Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: a meta-analysis of individual patient data from randomised controlled trials, Lancet Oncol. 15 (9) (2014) 986–996.

[34] S. Nand, M. Othus, J.E. Godwin, C.L. Willman, T.H. Norwood, D.S. Howard, et al., A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia, Blood 122 (20) (2013) 3432–3439.

[35] W. Fiedler, S. Kuyler, M. Krebenco, M. Janning, J. Krauter, M. Schittenhelm, et al., A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukemia and activating FLT3 mutations, Br. J. Haematol. 169 (5) (2015) 694–700.

[36] F. Zhou, Z. Ge, D. Chen, Quizartinib (AC220): a promising option for acute myeloid leukemia, Drug Des. Devel. Ther. 13 (2019) 1117–1125.

[37] E. Papaemmanuil, H. Dohner, P.J. Campbell, Genomic classification in acute myeloid leukemia, N. Engl. J. Med. 375 (9) (2016) 900–901.

[38] A.M. Byas, S. Ahmad, M. Faheem, M.I. Naseer, T.A. Kumosani, M.H. Al-Qahtani, et al., Next generation sequencing of acute myeloid leukemia: influencing prognosis, BMC Genomics 1 (2015) S5 16 Suppl.